Pharmacology, Toxicology and Pharmaceutical Science
Dry Powder Inhaler
100%
Adhesive Agent
74%
Levodopa
35%
Excipient
33%
Lactose Permease
33%
Parkinson's Disease
31%
Isoniazid
31%
Lactose
28%
Inhalation Formulation
27%
Colistimethate
24%
Pharmacokinetics
23%
Tolerability
23%
Antibiotic Agent
20%
Cyclopia
17%
Cystic Fibrosis
17%
Salmeterol
15%
Leucine
14%
Drug Formulation
13%
Scanning Electron Microscopy
12%
Coughing
11%
Tobramycin
9%
Amikacin
9%
Pulmonary Drug Delivery
9%
Inhalation Device
9%
Salmeterol Xinafoate
8%
Particle-Size Distribution
8%
Glass Fiber
7%
Extensively Drug-Resistant Tuberculosis
7%
Hydroxychloroquine Sulfate
7%
Drug Delivery Device
7%
Drug Distribution
7%
Normal Human
7%
Hydroxychloroquine
7%
Pharmacokinetics
7%
Powder Formulation
7%
Chronic Obstructive Lung Disease
5%
Asthma
5%
Fluticasone Propionate
5%
Disease
5%
Keyphrases
Inhaler
17%
Inhalation
17%
Dry Powder Inhaler
15%
Off Periods
15%
Levodopa
11%
Parkinson Patients
11%
Dispersion Performance
11%
Pulmonary Administration
11%
Pulmonary Delivery
11%
Dry Powder Inhalation
10%
Leucine
9%
Recent Advances
7%
Adhesive Materials
7%
Content Effect
7%
Aclidinium
7%
Multidose Dry Powder Inhaler
7%
Genuair
7%
Drug-in-adhesive Patch
7%
Dry Powder Aerosol
7%
Patients with Parkinson's Disease
7%
Next Generation Impactor
7%
Trileucine
7%
Stability Optimization
7%
High-dose Isoniazid
7%
Antibiotics
7%
Tuberculosis
7%
Inhaled Levodopa
7%
Filling Equipment
7%
High Dose
7%
Hydroxychloroquine Sulfate
7%
Cystic Fibrosis
7%
Tobramycin
7%
Inhaled Dry Powder
7%
Pharmacokinetic Evaluation
7%
Tolerability
7%
Dry Powder
7%
Cyclops
7%
Formulation Variables
7%
Aerosol Characterization
6%
HandiHaler
5%
Breezhaler
5%
Mixture Properties
5%
Drug Type
5%
Drug Delivery Device
5%
